3 recruiting, 2 active not recruiting, 2 terminated, 1 not yet recruiting. 8 Phase 1, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Recruiting 3, Active not recruiting 2, Terminated 2, Not yet recruiting 1 |
| Phase 2 | 8 | Recruiting 3, Active not recruiting 2, Terminated 2, Not yet recruiting 1 |
Follow Tango Therapeutics, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| TNG462-C103: Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Vopimetostat in Combination With ERAS-0015 in PDAC and NSCLC Patients vopimetostat, ERAS-0015 - PDAC, PDAC - Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Not yet recruiting | Tango Therapeutics, Inc. | 188 | 2026-11-01 | 2026-10-27 |
| Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients TNG462, RMC-9805, RMC-6236 - PDAC, PDAC - Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Tango Therapeutics, Inc. | 183 | 2025-05-31 | 2026-10-23 |
| Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss TNG456, abemaciclib - Non Small Cell Lung Cancer, Glioma Glioblastoma Multiforme | Phase 1 / Phase 2 | Recruiting | Tango Therapeutics, Inc. | 191 | 2025-03-24 | 2026-10-21 |
| S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP S095035, TNG462 - MTAP-deleted Solid Tumors | Phase 1 / Phase 2 | Active not recruiting | Servier Bio-Innovation LLC | 61 | 2024-04-29 | 2026-10-13 |
| Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors TNG348, Olaparib - Breast Cancer, Ovarian Cancer | Phase 1 / Phase 2 | Terminated | Tango Therapeutics, Inc. | 7 | 2023-12-08 | 2024-08-13 |
| Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors TNG260, Pembrolizumab - Non Small Cell Lung Cancer, Solid Tumors, Adult | Phase 1 / Phase 2 | Active not recruiting | Tango Therapeutics, Inc. | 126 | 2023-06-12 | 2026-07-06 |
| Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors TNG462, Pembrolizumab - Locally Advanced Solid Tumor | Phase 1 / Phase 2 | Recruiting | Tango Therapeutics, Inc. | 225 | 2023-05-26 | 2026-09-08 |
| Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors TNG908 - Locally Advanced Solid Tumor | Phase 1 / Phase 2 | Terminated | Tango Therapeutics, Inc. | 110 | 2022-03-23 | 2026-04-15 |
Lung Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (3) · Cholangiocarcinoma (2) · Glioblastoma (2) · Mesothelioma (2) · Neurofibrosarcoma (2) · Sarcoma (2) · Adenocarcinoma of Lung (1) · Biliary Tract Neoplasms (1) · Brain Neoplasms (1) · Breast Neoplasms (1) · Glioma (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1) · Prostatic Neoplasms (1)
pembrolizumab (2) · abemaciclib (1) · olaparib (1)
United States (7) · France (3) · Spain (2) · Australia (1) · Germany (1) · Italy (1) · Japan (1)
Adam Crystal, MD, PhD (3) · Maxim Pimkin, MD, PhD (1) · Maxim Pimpkin, MD (1) · Maxim Pimpkin, MD, PhD (1)
2025 (1)